Citadel Advisors
KYTH

Citadel Advisors’s KYTHERA BIOPHARMACEUTICALS, INC COM KYTH Stock Holding History

Citadel Advisors’s Portfolio KYTH Stock Details KYTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q4 		– Sell
-2,400
Closed -$180K – 9745
2015
Q3 		$180K Sell
2,400
-14,000
-85% -$1.05M ﹤0.01% 6290
2015
Q2 		$1.24M Sell
16,400
-600
-4% -$32.1K ﹤0.01% 3702
2015
Q1 		$853K Buy
17,000
+12,300
+262% +$516K ﹤0.01% 4143
2014
Q4 		$163K Buy
4,700
+3,700
+370% +$129K ﹤0.01% 6207
2014
Q3 		$33K Buy
+1,000
New +$35.2K ﹤0.01% 7175
2014
Q2 		– Sell
-800
Closed -$32K – 8644
2014
Q1 		$32K Sell
800
-200
-20% -$8.95K ﹤0.01% 7058
2013
Q4 		$37K Buy
+1,000
New +$41.5K ﹤0.01% 6201

Citadel Advisors's KYTH Position: Q4 2015 in Review

Citadel Advisors sold out of KYTHERA BIOPHARMACEUTICALS, INC COM (KYTH) in Q4 2015, closing a stake of 45,657 shares — an estimated $3.42M sold.

Citadel Advisors first reported a position in KYTH in Q3 2013 and held it in 7 quarters. The position peaked at $45.6M in Q2 2015. 0 funds tracked by Wall St. Rank hold KYTH as of Q4 2015.

  • Citadel Advisors reported no remaining KYTHERA BIOPHARMACEUTICALS, INC COM position as of Q4 2015 after selling out during the quarter.
  • Citadel Advisors sold 45,657 KYTHERA BIOPHARMACEUTICALS, INC COM shares in Q4 2015, an estimated $3.42M.
  • Citadel Advisors first reported a position in KYTHERA BIOPHARMACEUTICALS, INC COM in Q3 2013 and held it in 7 quarters.
  • Citadel Advisors's KYTHERA BIOPHARMACEUTICALS, INC COM position peaked at $45.6M in Q2 2015.
  • 0 funds tracked by Wall St. Rank held KYTHERA BIOPHARMACEUTICALS, INC COM as of Q4 2015.

Based on Citadel Advisors's 13F filing for Q4 2015, filed 12 Feb 2016.